Financials

v3.22.2.2
CONDENSED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 4,450 $ 6,037
Restricted cash 262 295
Receivables 49 112
Inventory 460 293
Prepaid expenses and other current assets 512 480
Discontinued operations - current assets 14 12
Total current assets 5,747 7,229
Property and equipment, net 269 420
Oher assets 48 48
Operating lease right-of-use assets 212 297
Total assets 6,276 7,994
Current liabilities:    
Accounts payable 812 795
Accrued clinical trials expenses 10 9
Other accrued liabilities 557 314
Operating lease liability, current 120 112
Deferred grant revenue 261 295
Discontinued operations – current liabilities 870 1,144
Total current liabilities 2,630 2,669
Operating lease liability, noncurrent 96 187
Total liabilities 2,726 2,856
Stockholders’ equity:    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized 14,629,217 and 9,914,158 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively. 15 10
Additional paid-in capital 387,230 381,183
Accumulated deficit (383,695) (376,055)
Total stockholders’ equity 3,550 5,138
Total liabilities and stockholders’ equity $ 6,276 $ 7,994

Source

v3.22.2.2
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:        
Total revenues $ 95 $ 264 $ 436 $ 1,391
Operating expenses:        
Cost of goods sold 199
Research and development 932 1,193 3,315 4,716
General and administrative 1,806 979 4,745 3,341
Total operating expenses 2,738 2,172 8,060 8,256
Loss from operations (2,643) (1,908) (7,624) (6,865)
Other income (expense):        
Interest income (expense), net 21 26 (2)
Gain on debt extinguishment 661
Other expense, net (16) (7) (42) (30)
Other income (expense), net 5 (7) (16) 629
Net loss $ (2,638) $ (1,915) $ (7,640) $ (6,236)
Basic and diluted net loss per common share $ (0.18) $ (0.19) $ (0.59) $ (0.64)
Weighted average shares used in computing basic and diluted net loss per common share 14,629 9,864 13,031 9,675
License and Service [Member]        
Revenues:        
Total revenues $ 4 $ 4 $ 9 $ 9
Product [Member]        
Revenues:        
Total revenues 36 236
Grant [Member]        
Revenues:        
Total revenues $ 91 $ 224 $ 427 $ 1,146

Source

v3.22.2.2
CONDENSED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss $ (7,640) $ (6,236)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 151 168
Non-cash interest expense 2
Stock-based milestone payment 50
Non-cash gain on debt extinguishment (661)
Stock-based compensation 1,038 1,359
Other 2 (8)
Changes in operating assets and liabilities:    
Receivables 63 459
Inventory (167) 199
Prepaid expenses and other assets (34) (170)
Accounts payable (182) (1,628)
Deferred grant revenue (34)
Other accrued liabilities 149 (302)
Net cash used in operating activities (6,604) (6,818)
Cash flows from investing activities:    
Purchases of property and equipment (18)
Net cash used in investing activities (18)
Cash flows from financing activities:    
Net proceeds from equity offering 4,980 8,841
Net proceeds from the exercises of common stock warrants 4
Net cash provided by financing activities 4,984 8,841
Net increase (decrease) in cash, cash equivalents and restricted cash (1,620) 2,005
Cash, cash equivalents and restricted cash at beginning of period 6,332 5,413
Cash, cash equivalents and restricted cash at end of period 4,712 7,418
Cash and cash equivalents 4,450 7,418
Restricted cash 262
Cash, cash equivalents and restricted cash shown in the condensed statements of cash flows $ 4,712 $ 7,418

Source